Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,738 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Silver Spring, Maryland • Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Consciousness, Psilocybin, and Well-Being

NCT05592379
Conditions
Healthy, Psychedelic Experiences, Sleep
Interventions
Psilocybin, Clonidine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation

NCT00964782
Conditions
Fontan Circulation
Interventions
Sildenafil, Placebo, Sildenafil 2, Placebo 2
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study Using GSK2330672

NCT01416324
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
Interventions
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Sutezolid, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Friedreich's Ataxia
Interventions
Interferon γ-1b, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers

Physiologic Monitoring of Antidepressant Treatment Response

NCT00759317
Conditions
Depression
Interventions
venlafaxine (Effexor)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Post-Operative Ileus (POI)
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

NCT01415440
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Concussion, Mild Traumatic Brain Injury
Interventions
Docosahexaenoic acid (DHA), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Plano, Texas
Conditions
Autism Spectrum Disorder, Aggression, Irritability
Interventions
Transdermal nicotine, Transdermal placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Conditions
Heavy Drinking, HIV, Alcohol Dependence
Interventions
Topiramate, Medical Management, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Overweight, Healthy Subjects
Interventions
SAR441255, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Multiple Sclerosis
Interventions
tDCS
Device
Lead sponsor
Colorado State University
Other
Eligibility
30 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon